1 hysiologic phenomenon, adversely affects the
hepatic allograft.
2 ibute to the comparative immune privilege of
hepatic allografts.
3 ntial use to attenuate the immunogenicity of
hepatic allografts.
4 Controlled NHBDs contributed 5% of
hepatic allografts (
8/164) from August 1996 through June
5 nity, autoimmunity, and in the regulation of
hepatic allograft acceptance.
6 e of immune activation were monitored in the
hepatic allograft and in the host spleen by analyses of
7 ity of illness, including poorly functioning
hepatic allograft and renal failure may be the major det
8 for the treatment of primary nonfunction of
hepatic allografts and fulminant hepatic failure.
9 nib-eluting beads (SEBs) in rabbits with VX2
hepatic allografts and to investigate treatment effects
10 tients (70.3%) were alive with their initial
hepatic allograft at the conclusion of the study period
11 ient survival among adult recipients of NHBD
hepatic allografts compared with recipients of HBD liver
12 ion between donor cardiopulmonary arrest and
hepatic allograft dysfunction.
13 Fifteen patients received a
hepatic allograft from a controlled NHBD donor.
14 nd 16 anti-HBs-, HbsAg- patients received an
hepatic allograft from a donor positive for anti-HBc.
15 Twenty-five of 48 recipients of a
hepatic allograft from a donor positive only for anti-HB
16 Twenty-five of 41 naive recipients of a
hepatic allograft from an anti-HBc positive donor were s
17 ts positive only for anti-HBc who received a
hepatic allograft from an anti-HBc-positive donor were s
18 onor organs occasionally mandates the use of
hepatic allografts from anti-HBc+ donors in recipients w
19 infection in anti-HBs-, HbsAg- recipients of
hepatic allografts from anti-HBc+ donors.
20 Hepatic allografts from anti-HBc-positive donors frequen
21 Hepatic allografts from donors positive only for anti-HB
22 By contrast,
hepatic allografts from donors treated with the hematopo
23 Hepatic allografts from donors who have suffered a brief
24 Recipients of
hepatic allografts from donors with antibodies to HBV we
25 Since suitable recipients for
hepatic allografts from donors with antibodies to hepati
26 ans, there is renewed interest in the use of
hepatic allografts from NHBDs.
27 Hepatic allografts from non-heart-beating donors (NHBD)
28 All surviving patients have normal
hepatic allograft function.
29 suggesting PGE1 infusion improves immediate
hepatic allograft function.
30 were split in situ and used as reduced-size
hepatic allografts in four recipients.
31 Hepatic allograft inflammation grade >/=2 and fibrosis s
32 on tests are elevated in an organ donor, the
hepatic allograft is suitable for OLT if the liver damag
33 Preservation-reperfusion injury of
hepatic allografts is thought to be associated with Kupf
34 reviews the use of plasmapheresis in primary
hepatic allograft nonfunction (PNF).
35 nce of brief donor cardiopulmonary arrest on
hepatic allograft outcome in human liver transplantation
36 es from 901 adult tacrolimus-treated primary
hepatic allograft recipients between August 1995 and Sep
37 (PBC), graft-versus-host disease (GVHD), and
hepatic allograft rejection (HAR), also occurs in the B1
38 Hepatic allograft rejection remains an important problem
39 utcomes included 1-year survival, cardiac or
hepatic allograft rejection, and infection.
40 GST may be useful in the management of early
hepatic allograft rejection.
41 markers may be beneficial to diagnose early
hepatic allograft rejection.
42 serologic markers in the management of early
hepatic allograft rejection.
43 data demonstrate that the failure of primary
hepatic allografts remains a major problem in pediatric
44 However, the effect of HLA matching for
hepatic allografts remains poorly defined.
45 rest in organ donors did not affect post-OLT
hepatic allograft survival and function.
46 The overall
hepatic allograft survival rate was equivalent to the ov
47 d the association between HLA mismatches and
hepatic allograft survival, disease recurrence, and immu
48 In both the native liver and
hepatic allograft,
the lymphoma presented as a sparse cy
49 Donor warm ischemic time may predispose
hepatic allografts to an increased incidence of ischemic
50 The loss of
hepatic allografts to the rejection processes is now rel
51 are homozygous at all HLA loci as donors of
hepatic allografts to their children.
52 g evidence that PSC frequently recurs in the
hepatic allograft using strict inclusion and exclusion c
53 HBIG can protect against reinfection of the
hepatic allograft with the YMDD HBV escape mutant.